ClinicalTrials.gg
Not yet recruitingNCT07470164ETS4Updated Apr 6, 2026

A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD

A Phase 3 interventional study of Botulinum toxin A and bilateral medial rectus recession in Esotropia, sponsored by Jaeb Center for Health Research. Not yet recruiting. Open to participants aged 4 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
4 Months to 17 Years
Sex
All
01

Study summary

Childhood esotropia (ET) is a common cause of visual disability, and its early management is critical for optimal visual and developmental outcomes.

The proposed study addresses a need to evaluate botulinum toxin A (BTX-A) as a less invasive, cost-effective alternative to incisional strabismus surgery. If BTX-A is demonstrated to be non-inferior to incisional strabismus surgery in treating ET >10 to ≤30PD, this could reduce surgical and anesthesia-related risks in infants, lower the economic burden on families and healthcare systems, and reduce disparities in access to care, particularly in underserved settings where surgical resources are limited.

Read the detailed description

After receiving informed consent, participants with ET >10 to ≤30PD who are otherwise eligible will be randomly assigned to treatment with BTX-A or incisional strabismus surgery; and seen 6 weeks, 6- and 12- months after surgery.

The primary outcome is the cumulative probability of motor alignment success by 12 months. Success is defined as the absence of failure by 12 months.

02

Conditions studied

  • Esotropia

Keywords

  • strabismus
  • pediatric
  • botox
  • botulinum toxin a
03

In context

Esotropia

36 studies on the registry are indexed under Esotropia; 11 are open to participants now.

This study's planned enrollment of 244 is above the median of 78 across 23 interventional studies indexed under Esotropia.

Browse Esotropia studies →

Lead sponsor

Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. A constant or intermittent ET needing intervention with BTX-A or surgery in the judgement of the investigator meeting one of the criteria below:

    Infantile Esotropia (IET)

    • Onset prior to six months of age by parental history.
    • Angle measuring >10 to ≤ 30 PD by PACT in the primary position at distance fixation on an accommodative target.

    Acquired Non-accommodative Esotropia (ANAET)

    • Onset after six months of age by parental history
    • Angle decreases less than 10 PD by PACT in the primary position at distance fixation with hyperopic correction.
    • Residual angle measuring >10 to ≤ 30 PD by SPCT in the primary position at distance fixation on an accommodative target.

    Acquired Partially Accommodative Esotropia (APAET)

    • Onset after six months of age by parental history
    • Angle decreases 10 PD or more by PACT in the primary position at distance fixation with correction.
    • Residual angle measuring >10 to ≤ 30 PD by SPCT in the primary position at distance fixation on an accommodative target.
  2. Age at enrollment:

    • For IET: > 4 months to \<17 years old
    • For ANAET or APAET: >6 months to \<17 years old
  3. No myopia ≥ 6.00D SE
  4. Current Spectacle Correction at Time of Enrollment

    • For IET: No spectacle wear prior to enrollment.
    • For ANAET or APAET: Must be wearing spectacles if significant refractive error as defined below based upon a cycloplegic refraction within 6 months of enrollment. If no significant refractive error, spectacles are at investigator discretion. In either case full hyperopic correction by cycloplegia worn for at least 2 weeks.
  5. Requirements for Spectacle Correction (if worn)

    • If myopia is \< 6.00D SE, then full CR must be worn for at least 2 weeks.
    • For children \< 5 years of age who have significant hyperopic refractive error (CR ≥ +2.50D SE), full hyperopic correction, determined by CR must have been worn for at least 2 weeks.
    • For children ≥ age 5 years, with significant hyperopic refractive error who are unable to tolerate correction of full CR due to blur, then maximally-tolerated hyperopic correction determined both with and without cycloplegia is prescribed and must be worn for at least 2 weeks.
    • For patients who do not have significant hyperopic refractive error (CR \< +2.50D SE), whether to prescribe spectacles is at investigator discretion. However, if the investigator elects to prescribe spectacles, the full tolerated hyperopic correction determined with and without cycloplegia must have been worn for at least 2 weeks.
  6. Parent or legal guardian available for follow-up, has home phone (or access to phone), and willing to be contacted by Jaeb Center staff
  7. Gestational age > 34 weeks
  8. Birth weight > 1500 grams
  9. No use of atropine within the last two weeks.
  10. No history of CNS disease (e.g., IVH, PVL, meningitis, developmental abnormalities of the brain, hydrocephalus, cerebral palsy, hypoxic ischemic encephalopathy)
  11. No significant developmental delay in the investigator's judgment (isolated speech delay excepted)
  12. No limitation of abduction consistent with paralytic or restrictive myopathy (minor limitation of abduction due to cross fixation is acceptable)
  13. No craniofacial malformation affecting the orbits
  14. No prior BTX-A injection for strabismus
  15. No prior extraocular muscle surgery or intraocular surgery
  16. No structural ocular abnormalities (e.g., media opacity, optic atrophy, optic nerve hypoplasia, retinal detachment)
  17. No immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is investigative site personnel directly affiliated with this study or who is an employee of the Jaeb Center for Health Research.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
244 participants (estimated)

Study arms

  • Experimental
    Botox

    Group assigned to receive BTX-A injection

    Drug: Botulinum toxin A

  • Active comparator
    Surgery

    Group assigned to receive Graded bilateral medial rectus recession

    Procedure: bilateral medial rectus recession

Interventions

  • BTX-A 4.0 units to each medial rectus

    Also known as: Botox

  • Procedurebilateral medial rectus recession

    Graded bilateral medial rectus recession

    Also known as: BMRrec

06

What researchers measure

Primary outcomes

  1. Motor Alignment Success

    The primary efficacy outcome will be motor alignment success defined as follows: 1. Success is defined as the absence of failure by 1 year. 2. Failure is defined as any of the following post-randomized treatment (BOTOX or SURGERY) up to 1 year: * ET at distance (determined by a cover/uncover test) with a magnitude of \>10 PD by SPCT at or after the 6-month masked exam. * XT at distance at any time during the exam (determined by a cover/uncover test) with a magnitude of \> 10 PD by SPCT at or after the 6-month masked exam. * Second surgery or injection at any time after the initial surgery/injection through 12 months post-procedure.

    Time frame: 1 Year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available after publication of each primary manuscript.

Access criteria: Users accessing the data must enter an email address.

Data sharing details ↗ · public.jaeb.org

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07470164
Collaborators
National Eye Institute (NEI), Pediatric Eye Disease Investigator Group
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Apr 6, 2026

Study contacts

Raymond T Kraker, MSPH
Contact
rkraker@jaeb.org
813-975-8690
PEDIG Protocol Monitor
Contact
pedig@jaeb.org
813-975-8690

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion